After 2 weeks of l-DOPA treatment, the SKF 81297-induced dyskinesia nearly doubled in magnitude, while activation of PKA and ERK1/2 was downregulated (Fig. 6b,d). The gene discussed is MAPK3; the disease is Dyskinesia.